Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan

Takuya Imatoh, Kimie Sai, Mayu Takeyama, Katsunori Segawa, Takanori Yamashita, Naoki Nakashima, Yoko Kataoka, Hideto Yokoi, Tatsuo Hiramatsu, Kazuhiko Ohe, Michio Kimura, Katsuhito Hori, Junichi Kawakami, Yoshiro Saito

研究成果: Contribution to journalArticle

抜粋

What is known and Objective: Since its introduction in April 2012, denosumab has been administered to approximately 7,300 patients as of August 2012, and 32 cases of serious hypocalcaemia after denosumab administration, including two deaths, have been reported in Japan. A Dear Healthcare Professional Letter of Rapid Safety Communication (‘Blue letter’) was released to warn about the risks of hypocalcaemia associated with denosumab. The goal of this study therefore was to measure the impact of regulatory action on denosumab-induced hypocalcaemia in Japan by using an electronic medical information database (MID). Methods: We used two different aggregated data sets based on MIDs (data sets one and two). The patients studied were those who were newly prescribed denosumab or zoledronic acid between April 2012 and September 2014. We assessed four indicators: (a) the proportion of patients with calcium supplementation at the initial denosumab treatment, (b) the proportion of patients who underwent a serum calcium test, (c) the average number of serum calcium tests performed and (d) the prevalence of hypocalcaemia. All indices were aggregated by every 3 months. To evaluate the impact of regulatory action, we used difference in difference (DID) analysis. Results and Discussion: The proportion of patients with calcium supplementation at the initial denosumab treatment increased year by year in both data sets. The average number of serum calcium tests increased year by year in data set two. There was a significant difference in the prevalence of hypocalcaemia in data set two. This suggests that the estimate of impact of the regulatory action may vary according to the database. In DID analysis, however, significant influences of the regulatory action on combination use with a calcium supplement were detected in both data sets. What is New and Conclusion: There was a significant influence on combination use of denosumab with vitamin D and/or calcium supplement in both data sets. That there was no apparent increase in the prevalence of denosumab-induced hypocalcaemia, suggests that the regulatory action had an impact in the clinical setting studied. Such regulatory actions may play an important role in the promotion of drug safety.

元の言語英語
ページ(範囲)788-795
ページ数8
ジャーナルJournal of Clinical Pharmacy and Therapeutics
44
発行部数5
DOI
出版物ステータス出版済み - 10 1 2019

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

フィンガープリント Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Imatoh, T., Sai, K., Takeyama, M., Segawa, K., Yamashita, T., Nakashima, N., Kataoka, Y., Yokoi, H., Hiramatsu, T., Ohe, K., Kimura, M., Hori, K., Kawakami, J., & Saito, Y. (2019). Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan. Journal of Clinical Pharmacy and Therapeutics, 44(5), 788-795. https://doi.org/10.1111/jcpt.13004